AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Hutchmed (China) Limited

Net Asset Value Oct 20, 2015

10503_dirs_2015-10-20_14b0f7b7-9253-45e5-8bc5-10ae364996d9.html

Net Asset Value

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8611C

Hutchison China Meditech Limited

20 October 2015

Director's Share Dealing

London: Tuesday, 20 October 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) received notification on 19 October 2015 that Mr Christopher Nash, Independent Non-executive Director, has:

·      purchased jointly with his spouse 4,512 ordinary shares of US$1.00 each in Chi-Med (the "Shares") at a price of GBP21.95 per Share on 19 October 2015; and

·      transferred 5,626 Shares at GBP21.65 per Share from one of his investment funds to his another investment fund (jointly held with his spouse) on 19 October 2015.

Following the above transactions, the combined holding of Mr Nash and his spouse is 36,442 Shares, representing approximately 0.06% of the current issued share capital of Chi-Med.

Ends

Enquiries

Chi-Med   Christian Hogg, CEO Telephone:        +852 2121 8200
Panmure Gordon (UK) Limited

   Richard Gray

   Andrew Potts
Telephone:        +44 20 7886 2500
Citigate Dewe Rogerson   Anthony Carlisle

   David Dible
Telephone:        +44 20 7638 9571

Mobile:              +44 7973 611 888

Mobile:              +44 7967 566 919

About Chi-Med

Chi-Med is a China-based globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products.  Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market.  Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001).  For more information, please visit: www.chi-med.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSLLFVVIDLIFIE

Talk to a Data Expert

Have a question? We'll get back to you promptly.